| Ling, Yang Ya |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Li, Ling |
AK0529-2007, NCT06775405: A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants |
|
|
| Recruiting | 3 | 180 | RoW | AK0529, Placebo | Shanghai Ark Biopharmaceutical Co., Ltd. | Respiratory Synctial Virus Infections | 08/25 | 09/25 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
| Completed | 3 | 257 | RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases | 07/24 | 07/24 | | |
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | 2 | 185 | RoW | HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor | Hutchison Medipharma Limited | Marginal Zone Lymphoma, Follicular Lymphoma | 04/24 | 12/24 | | |
NCT06455410: GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 216 | RoW | GP, Adebrelimab, concurrent chemoradiotherapy (CCRT) | Sun Yat-sen University | Nasopharyngeal Carcinoma | 06/26 | 06/28 | | |
NCT06730373: First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) |
|
|
| Recruiting | 2 | 110 | RoW | Disitamab Vedotin, Sintilimab, S-1, Trastuzumab, Oxaliplatin, Capecitabine, 5-FU, Cisplatin | Qilu Hospital of Shandong University | HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma | 12/26 | 12/27 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
| Recruiting | N/A | 4500 | RoW | | Harbin Medical University, Abbott | Acute Myocardial Infarction | 07/21 | 12/22 | | |
| Recruiting | N/A | 10000 | RoW | Coronary angiography, CT angiography of aorta, CTA, CT angiography of pulmonary arteries., Electrocardiogram, ECG, Cardiac Troponin, Biomarkers of myocardial injury | West China Hospital | Chest Pain, Acute Aortic Dissection, Pulmonary Embolism, Acute Myocardial Infarction Type 1, Acute Coronary Syndrome | 10/21 | 10/22 | | |
NCT05227677: Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 200 | RoW | GA guided anti-diabetic therapy adjustment, current guidelines to adjust treatment | Asahi Kasei Pharma Corporation | Type 2 Diabetes Mellitus | 08/24 | 12/24 | | |
NCT06276309: Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors |
|
|
| Recruiting | N/A | 300 | RoW | | Fujian Maternity and Child Health Hospital | Neuroendocrine Neoplasm, China, Women, Cervical Cancer, Cervical Lesion | 12/24 | 02/25 | | |
NCT05282095: Effect of HPV Integration on Prognosis of Young Women With CIN2 in China |
|
|
| Recruiting | N/A | 300 | RoW | Follow up | Fujian Maternity and Child Health Hospital | Cervical Intraepithelial Neoplasia, HPV Infection, Virus Integration, HSIL, High Grade Squamous Intraepithelial Lesions | 12/25 | 05/26 | | |
| Recruiting | N/A | 3000 | RoW | | Chen Li | Children Behavior Problem, Pregnancy | 07/25 | 12/28 | | |
NCT05597709: Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China |
|
|
| Recruiting | N/A | 2900 | RoW | Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination | Wuxi Hisky Medical Technology Co Ltd, Zhongda Hospital, Medical School, Southeast University, Suzhou Municipal Hospital, Suzhou Fifth People's Hospital, Xuzhou Mining Group General Hospital, Nantong First People's Hospital, Changzhou Second People's Hospital, Huaian Second People's Hospital, Huaian Hospital, Taizhou Jiangyan Traditional Chinese Medicine Hospital, Yangzhou Jiangdu People's Hospital, Huaian Xuyi County People's Hospital | Type 2 Diabetes Mellitus in Remission, Metabolic Associated Fatty Liver Disease | 06/23 | 06/27 | | |
NCT05707819: Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 43 | RoW | Sintilimab (PD-1 Antibody), PD-1 | Cancer Hospital of Guangxi Medical University | Nasopharyngeal Carcinoma, Sintilimab | 12/23 | 12/28 | | |
